Export bibliographic data
Literature by the same author
plus on the publication server
plus at Google Scholar


Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany

Title data

Runge, Melanie ; Krensel, Magdalene ; Westermann, Claudia ; Bindl, Dominik ; Nagels, Klaus ; Augustin, Matthias ; Nienhaus, Albert:
Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany.
In: International Journal of Environmental Research and Public Health. Vol. 17 (9 January 2020) Issue 2 . - No. 440.
ISSN 1660-4601
DOI: https://doi.org/10.3390/ijerph17020440

Official URL: Volltext

Abstract in another language

Around 1% of the world’s population is infected with hepatitis C. The introduction of new direct-acting antiviral agents (DAAs) in 2014 has substantially improved hepatitis C treatment outcomes. Our objective was to evaluate the long-term cost effectiveness of DAAs in health care personnel (HP) with confirmed occupational diseases in Germany. A standardised database from a German statutory accident insurance was used to analyse the cost-effectiveness ratio for the DAA regimen in comparison with interferon-based triple therapies. Taking account of the clinical progression of the disease, a Markov model was applied to perform a base case analysis for a period of 20 years. The robustness of the results was determined using a univariate deterministic sensitivity analysis. The results show that treatment with DAAs is more expensive, but also more effective than triple therapies. The model also revealed that the loss of 3.23 life years can be averted per patient over the 20 years. Compared to triple therapies, DAA treatment leads to a higher sustained virologic response (SVR). Although this results in a decrease of costs in the long term, e.g., pension payments, DAA therapy will cause greater expense in the future due to the high costs of the drugs.

Further data

Item Type: Article in a journal
Refereed: Yes
Keywords: hepatitis C; cost-effectiveness analysis; interferon-free therapies; direct-acting antiviral agents; occupational disease
Institutions of the University: Faculties > Faculty of Law, Business and Economics > Chair Healthcare Management and Research > Chair Healthcare Management and Research - Univ.-Prof. Dr. Klaus Nagels
Result of work at the UBT: Yes
DDC Subjects: 300 Social sciences > 300 Social sciences, sociology and anthropology
300 Social sciences > 330 Economics
600 Technology, medicine, applied sciences > 600 Technology
600 Technology, medicine, applied sciences > 610 Medicine and health
Date Deposited: 10 Jan 2020 09:46
Last Modified: 10 Jan 2020 09:46
URI: https://eref.uni-bayreuth.de/id/eprint/53700